Skip to main content
SpringerLink
Log in

Perkutaner Aortenklappenersatz – Pro

Perkutane Aortenklappenimplantation: Chance oder Risiko?

Percutaneous Aortic Valve Replacement – Pro

  • Published:
Herz Kardiovaskuläre Erkrankungen Aims and scope Submit manuscript

Zusammenfassung

Der perkutane Aortenklappenersatz ist aktuell auf bestem Wege, die therapeutische Praxis bei degenerativen Aortenklappenstenosen zu revolutionieren. Zwei unterschiedliche Techniken sind derzeit im klinischen Einsatz: die ballonexpandierbare Edwards-Klappenprothese und die selbstexpandierbare Core-valve-ReValving-Prothese. Nach initialer Lernkurve und Prothesenmodifikationen erzielen die aktuellen Produktgenerationen akute Erfolgsraten von > 95% mit niedriger peri- und postinterventioneller Komplikationsrate. Im Rahmen dieser Artikels wird ein Überblick über den aktuellen Stand der Technik gegeben.

Abstract

Percutaneous aortic valve replacement is presently on its way to revolutionize the current treatment practice for patients with degenerative aortic valve stenosis. Two different techniques are available: the balloonexpandable Edwards valve prosthesis and the selfexpanding CoreValve ReValving prosthesis. After an initial learning curve as well as device modifications, use of the current generations has a > 95% success rate with a low peri- and postinterventional complication rate. In this article, an overview on the current status of this technique will be provided.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933–89.

    Article  PubMed  Google Scholar 

  2. Mancini DM, Eisen H, Kussmaul W et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778–86.

    PubMed  CAS  Google Scholar 

  3. Ponikowski P, Francis DP, Piepoli MF et al. Enhanced ventilatory response to exercise in patients with chronic heart failure and preserved exercise tolerance: marker of abnormal cardiorespiratory reflex control and predictor of poor prognosis. Circulation 2001;103:967–72.

    PubMed  CAS  Google Scholar 

  4. Ponikowski P, Anker SD, Chua TP et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997;79:1645–50.

    Article  PubMed  CAS  Google Scholar 

  5. Ponikowski P, Chua TP, Anker SD et al. Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation 2001;104:544–9.

    Article  PubMed  CAS  Google Scholar 

  6. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358:2148–59.

    Article  PubMed  CAS  Google Scholar 

  7. Maisel A, Mueller C, Adams K Jr et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;10:824–39.

    Article  PubMed  CAS  Google Scholar 

  8. Lainscak M, Haehling S von, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int J Cardiol 2009:in press (Epub 2009 Jan 12; PMID 19144431).

  9. Haehling S von, Jankowska EA, Morgenthaler NG et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1973–80.

    Article  Google Scholar 

  10. Oral I, Mistrik J, Naplava R. Clinical status and B-type natriuretic peptide levels in patients with heart failure at hospital discharge. Herz 2007;32:583–8.

    Article  PubMed  Google Scholar 

  11. Troughton RW, Frampton CM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126–30.

    Article  PubMed  CAS  Google Scholar 

  12. Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol 2007;49:1733–9.

    Article  PubMed  CAS  Google Scholar 

  13. Haehling S von, Lainscak M, Springer J et al. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009:in press (Epub 2008 Nov 14; PMID 19061914).

  14. Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050–3.

    Article  PubMed  CAS  Google Scholar 

  15. Anker SD, Negassa A, Coats AJS et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet 2003;361:1077–83.

    Article  PubMed  CAS  Google Scholar 

  16. Lainscak M, Filippatos GS, Gheorghiade M et al. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol 2008;101:8E–10E.

    Article  PubMed  Google Scholar 

  17. Evans WJ, Morley JE, Argilés J et al. Cachexia: a new definition. Clin Nutr 2008;27:793–9.

    Article  PubMed  CAS  Google Scholar 

  18. Springer J, Filippatos G, Akashi YJ et al. Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol 2006;21:311–8.

    Article  Google Scholar 

  19. Strassburg S, Springer J, Anker SD. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol 2005;37:1938–47.

    Article  PubMed  CAS  Google Scholar 

  20. Lainscak M, Keber I, Anker SD. Body composition changes in patients with systolic heart failure treated with beta blockers: a pilot study. Int J Cardiol 2006;106:319–22.

    Article  PubMed  Google Scholar 

  21. Anker SD, Steinborn W, Strassburg S. Cardiac cachexia. Ann Med 2004;36:518–29.

    Article  PubMed  Google Scholar 

  22. Lainscak M, Andreas S, Scanlon PD et al. Ghrelin and neurohumoral antagonists in the treatment of cachexia associated with cardiopulmonary disease. Intern Med 2006;45:837.

    Article  PubMed  Google Scholar 

  23. Springer J, Haehling S von, Anker SD. The need for a standardized definition for cachexia in chronic illness. Nat Clin Pract Endocrinol Metab 2006;2:416–7.

    Article  PubMed  Google Scholar 

  24. Szachniewicz J, Petruk-Kowalczyk J, Majda J et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol 2003;90:303–8.

    Article  PubMed  CAS  Google Scholar 

  25. Kalra PR, Bolger AP, Francis DP et al. Effect of anemia on exercise tolerance in chronic heart failure in men. Am J Cardiol 2003;91:888–91.

    Article  PubMed  Google Scholar 

  26. Sharma R, Francis DP, Pitt B et al. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 2004;25:1021–8.

    Article  PubMed  CAS  Google Scholar 

  27. Komajda M, Anker SD, Charlesworth A et al. The impact of new onset anemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006;27:1440–6.

    Article  PubMed  Google Scholar 

  28. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107:223–5.

    Article  PubMed  Google Scholar 

  29. Ponikowski P, Anker SD, Szachniewicz J et al. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007;49:753–62.

    Article  PubMed  CAS  Google Scholar 

  30. Okonko DO, Grzeslo A, Witkowski T et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency. FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103–12.

    Article  PubMed  CAS  Google Scholar 

  31. Kalantar-Zadeh K, Horwich TB, Oreopoulos A et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 2007;10:433–42.

    Article  PubMed  Google Scholar 

  32. Potapov EV, Loebe M, Anker S et al. Impact of body mass index on outcome in patients after coronary artery bypass grafting with and without valve surgery. Eur Heart J 2003;24:1933–41.

    Article  PubMed  Google Scholar 

  33. Davos CH, Doehner W, Rauchhaus M et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail 2003;9:29–35.

    Article  PubMed  Google Scholar 

  34. Kenchaiah S, Pocock SJ, Wang D et al. Body mass index and prognosis in patients with chronic heart failure. Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007;116:627–36.

    Article  PubMed  Google Scholar 

  35. Pocock SJ, McMurray JJ, Dobson J et al. Weight loss and mortality risk in patients with chronic heart failure in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008;29:2641–50.

    Article  PubMed  Google Scholar 

  36. Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933–40.

    Article  PubMed  CAS  Google Scholar 

  37. Anker SD, Clark AL, Winkler R et al. Statin use and survival in patients with chronic heart failure - results from two observational studies with 5200 patients. Int J Cardiol 2006;112:234–42.

    Article  PubMed  Google Scholar 

  38. Haehling S von, Anker SD. Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism? Heart 2005;91:1–2.

    Article  Google Scholar 

  39. Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248–61.

    Article  PubMed  CAS  Google Scholar 

  40. GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231–9.

    Article  PubMed  CAS  Google Scholar 

  41. Kalantar-Zadeh K, Kuwae N, Wu DY et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 2006;83:202–10.

    PubMed  CAS  Google Scholar 

  42. Doehner W, Rauchhaus M, Ponikowski P et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005;46:1019–26.

    Article  PubMed  CAS  Google Scholar 

  43. Gerstein HC, Swedberg K, Carlsson J et al. The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure. Arch Intern Med 2008;168:1699–704.

    Article  PubMed  CAS  Google Scholar 

  44. Pfister R, Erdmann E. Diabetes mellitus and heart failure: Epidemiology and therapy. Herz 2008;33:178–83.

    Article  PubMed  Google Scholar 

  45. Landmesser U, Spiekermann S, Dikalov S et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002;106:3073–8.

    Article  PubMed  CAS  Google Scholar 

  46. Leyva F, Chua TP, Anker SD et al. Uric acid in chronic heart failure: a measure of the anaerobic threshold. Metabolism. 1998;47:1156–9.

    Article  PubMed  CAS  Google Scholar 

  47. Anker SD, Leyva F, Poole-Wilson PA et al. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart 1997;78:39–43.

    PubMed  CAS  Google Scholar 

  48. Leyva F, Anker SD, Godsland IF et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998;19:1814–22.

    Article  PubMed  CAS  Google Scholar 

  49. Kempf T, Haehling S von, Peter T et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1054–60.

    Article  PubMed  CAS  Google Scholar 

  50. Doehner W, Rauchhaus M, Florea VG et al. Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance. Am Heart J 2001;141:792–9.

    Article  PubMed  CAS  Google Scholar 

  51. Anker SD, Doehner W, Rauchhaus M et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991–7.

    Article  PubMed  Google Scholar 

  52. Doehner W, Schoene N, Rauchhaus M et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebocontrolled studies. Circulation 2002;105:2619–24.

    Article  PubMed  CAS  Google Scholar 

  53. Hare JM, Mangal B, Brown J et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008;51:2301–9.

    Article  PubMed  CAS  Google Scholar 

  54. Levine B, Kalman J, Mayer L et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236–41.

    PubMed  CAS  Google Scholar 

  55. Fuchs M, Drexler H. Mechanisms of inflammation in heart failure. Herz 2004;29:782–7.

    Article  PubMed  Google Scholar 

  56. Rauchhaus M, Doehner W, Francis DP et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060–7.

    PubMed  CAS  Google Scholar 

  57. Anker SD, Egerer KR, Volk HD et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997;79:1426–30

    Article  PubMed  CAS  Google Scholar 

  58. Sandek A, Bauditz J, Swidinski A et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1561–9.

    Article  PubMed  CAS  Google Scholar 

  59. Rauchhaus M, Coats AJS, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet 2000;356:930–3.

    Article  PubMed  CAS  Google Scholar 

  60. Niebauer J, Volk HD, Kemp M et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353:1838–42.

    Article  PubMed  CAS  Google Scholar 

  61. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123–30.

    Article  PubMed  Google Scholar 

  62. Torre-Amione G, Anker SD, Bourge RC et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 2008;371:228–36.

    Article  PubMed  CAS  Google Scholar 

  63. Lainscak M, Cleland JG, Lenzen MJ et al. Recall of lifestyle advice in patients recently hospitalised with heart failure: a EuroHeart Failure survey analysis. Eur J Heart Fail 2007;9:1095–103.

    Article  PubMed  Google Scholar 

  64. Goode KM, Nabb S, Cleland JGF et al. A comparison of patient and physician-rated New York Heart Association class in a community-based heart failure clinic. J Card Fail 2008;14:379–87.

    Article  PubMed  Google Scholar 

  65. O’Connor CM, Jiang W, Kuchibhatla M et al. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 2008;168:2232–7.

    Article  PubMed  Google Scholar 

  66. Chen H, Cohen P, Kasen S. Cohort differences in self-rated health: evidence from a three-decade, community-based, longitudinal study of women. Am J Epidemiol 2007;166:439–46.

    Article  PubMed  Google Scholar 

  67. Konstam V, Salem D, Pouleur H et al. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. Am J Cardiol 1996;78:890–5.

    Article  PubMed  CAS  Google Scholar 

  68. Farkas J, Nabb SL, Zaletel-Kragelj L et al. Self-rated health in patients with chronic heart failure: distribution and association with mortality. Eur J Heart Fail 2008;7:Suppl 1:94–5.

    Google Scholar 

  69. Anker SD, Coats AJS. Metabolic, functional, and haemodynamic staging for CHF? Lancet 1996;348:1530–1.

    Article  PubMed  CAS  Google Scholar 

  70. Aaronson K, Schwartz J, Chen T et al. Development and prospective validation of a clinical index to predict survival in ambulatry patients reffered for cardiac transplantation evaluation. Circulation 1997;95:2660–7.

    PubMed  CAS  Google Scholar 

  71. Levy WC, Mozaffarian D, Linker DT et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation 2006;113:1424–33.

    Article  PubMed  Google Scholar 

  72. May HT, Horne BD, Levy WC et al. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am J Cardiol 2007;100:697–700.

    Article  PubMed  CAS  Google Scholar 

  73. Mozaffarian D, Anker SD, Anand I et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation 2007;116:392–8.

    Article  PubMed  Google Scholar 

  74. Gottlieb SS. Prognostic indicators: useful for clinical care? J Am Coll Cardiol 2009;53:343–4.

    Article  PubMed  Google Scholar 

  75. Schulz-Menger J, Maisch B, Abdel-Aty H et al. Integrated biomarkers in cardiomyopathies. Herz 2007;32:458–72.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik – Kardiologie/Angiologie, HELIOS Klinikum Siegburg, Siegburg, Germany

    Eberhard Grube

  2. Medizinische Klinik – Kardiologie/Angiologie, HELIOS Klinikum Siegburg, Ringstraße 49, 53721, Siegburg, Germany

    Eberhard Grube

Authors
  1. Lutz Buellesfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eberhard Grube
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eberhard Grube.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buellesfeld, L., Grube, E. Perkutaner Aortenklappenersatz – Pro. Herz 34, 124–129 (2009). https://doi.org/10.1007/s00059-009-3213-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00059-009-3213-x

Schlüsselwörter:

Key Words:

Search

Navigation